A first in human study of cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD").
Phase of Trial: Phase 0
Latest Information Update: 12 Apr 2018
Price : $35 *
At a glance
- Drugs Marijuana (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors GB Sciences
- 12 Apr 2018 New trial record
- 10 Apr 2018 According to a GB Sciences media release, company is planning to file an Exploratory IND application to the US FDA. This study is expected to start in early 2019.